Nightstar Therapeutics Stock Price, News & Analysis (NASDAQ:NITE)

$13.51 +0.36 (+2.74 %)
(As of 02/25/2018 03:08 AM ET)
Previous Close$13.51
Today's Range$12.07 - $13.87
52-Week Range$10.05 - $24.93
Volume108,911 shs
Average Volume30,283 shs
Market Capitalization$390.03 million
P/E Ratio-27.02
Dividend YieldN/A
BetaN/A

About Nightstar Therapeutics (NASDAQ:NITE)

Nightstar Therapeutics logoNightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases. The Company’s lead product candidate, NSR-REP1, for the treatment of choroideremia, or CHM, is entering Phase III clinical development. The Company is also conducting a Phase I/II clinical trial with its second product candidate, NSR-RPGR, for the treatment of X-linked retinitis pigmentosa, or XLRP. The Company’s third product candidate, NSR-BEST1, is in preclinical development for the treatment of Best vitelliform macular dystrophy, or Best disease.

Receive NITE News and Ratings via Email

Sign-up to receive the latest news and ratings for NITE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:NITE
CUSIPN/A
Phone+44-20-76112077

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-27.02
Forward P/E Ratio-20.47
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees23
Outstanding Shares28,100,000

Nightstar Therapeutics (NASDAQ:NITE) Frequently Asked Questions

What is Nightstar Therapeutics' stock symbol?

Nightstar Therapeutics trades on the NASDAQ under the ticker symbol "NITE."

Where is Nightstar Therapeutics' stock going? Where will Nightstar Therapeutics' stock price be in 2018?

5 Wall Street analysts have issued 1 year price targets for Nightstar Therapeutics' stock. Their forecasts range from $25.00 to $40.00. On average, they expect Nightstar Therapeutics' stock price to reach $30.20 in the next twelve months. View Analyst Ratings for Nightstar Therapeutics.

Who are some of Nightstar Therapeutics' key competitors?

When did Nightstar Therapeutics IPO?

(NITE) raised $76 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and Chardan were co-managers.

When does Nightstar Therapeutics' lock-up period expire?

Nightstar Therapeutics' lock-up period expires on Tuesday, March 27th. Nightstar Therapeutics had issued 5,360,000 shares in its IPO on September 28th. The total size of the offering was $75,040,000 based on an initial share price of $14.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

Who owns Nightstar Therapeutics stock?

Nightstar Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Essex Investment Management Co. LLC (0.48%) and Chartwell Investment Partners LLC (0.40%). View Institutional Ownership Trends for Nightstar Therapeutics.

Who sold Nightstar Therapeutics stock? Who is selling Nightstar Therapeutics stock?

Nightstar Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Chartwell Investment Partners LLC. View Insider Buying and Selling for Nightstar Therapeutics.

Who bought Nightstar Therapeutics stock? Who is buying Nightstar Therapeutics stock?

Nightstar Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC. View Insider Buying and Selling for Nightstar Therapeutics.

How do I buy Nightstar Therapeutics stock?

Shares of Nightstar Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nightstar Therapeutics' stock price today?

One share of Nightstar Therapeutics stock can currently be purchased for approximately $13.51.

How big of a company is Nightstar Therapeutics?

Nightstar Therapeutics has a market capitalization of $390.03 million. Nightstar Therapeutics employs 23 workers across the globe.

How can I contact Nightstar Therapeutics?

Nightstar Therapeutics' mailing address is 215 Euston Road, LONDON, MA NW1 2BE, United Kingdom. The company can be reached via phone at +44-20-76112077 or via email at [email protected]


MarketBeat Community Rating for Nightstar Therapeutics (NITE)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  51 (Vote Outperform)
Underperform Votes:  38 (Vote Underperform)
Total Votes:  89
MarketBeat's community ratings are surveys of what our community members think about Nightstar Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Nightstar Therapeutics (NASDAQ:NITE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 3.003.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $30.20$30.20$24.75N/A
Price Target Upside: 106.71% upside106.71% upsideN/AN/A

Nightstar Therapeutics (NASDAQ:NITE) Consensus Price Target History

Price Target History for Nightstar Therapeutics (NASDAQ:NITE)

Nightstar Therapeutics (NASDAQ:NITE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/17/2018WedbushReiterated RatingOutperform -> Outperform$29.00 -> $31.00LowView Rating Details
1/3/2018Chardan CapitalInitiated CoverageBuy -> Buy$40.00HighView Rating Details
10/23/2017Leerink SwannInitiated CoverageOutperform -> Outperform$25.00N/AView Rating Details
10/23/2017Jefferies GroupInitiated CoverageBuy -> Buy$25.00N/AView Rating Details
10/23/2017BMO Capital MarketsInitiated CoverageOutperform$30.00N/AView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Earnings History for Nightstar Therapeutics (NASDAQ:NITE)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Nightstar Therapeutics (NASDAQ:NITE) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.66 EPS
Next Year EPS Consensus Estimate: $-1.62 EPS

Dividends

Dividend History for Nightstar Therapeutics (NASDAQ:NITE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Nightstar Therapeutics (NASDAQ NITE)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Nightstar Therapeutics (NASDAQ NITE) News Headlines

Source:
DateHeadline
-$0.20 Earnings Per Share Expected for Nightstar Therapeutics PLC (NITE) This Quarter-$0.20 Earnings Per Share Expected for Nightstar Therapeutics PLC (NITE) This Quarter
www.americanbankingnews.com - February 24 at 2:00 PM
 Nightstar Therapeutics PLC (NITE) Given Average Recommendation of "Strong Buy" by Analysts Nightstar Therapeutics PLC (NITE) Given Average Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - February 13 at 1:44 PM
Brokerages Anticipate Nightstar Therapeutics PLC (NITE) to Post ($0.19) EPSBrokerages Anticipate Nightstar Therapeutics PLC (NITE) to Post ($0.19) EPS
www.americanbankingnews.com - February 10 at 3:28 PM
Zacks: Nightstar Therapeutics PLC (NITE) Given Consensus Recommendation of "Strong Buy" by BrokeragesZacks: Nightstar Therapeutics PLC (NITE) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - February 6 at 10:40 AM
Zacks: Nightstar Therapeutics PLC (NITE) Given Average Recommendation of "Strong Buy" by BrokeragesZacks: Nightstar Therapeutics PLC (NITE) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - January 30 at 7:56 AM
 Analysts Expect Nightstar Therapeutics PLC (NITE) Will Post Earnings of -$0.19 Per Share Analysts Expect Nightstar Therapeutics PLC (NITE) Will Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - January 21 at 3:25 PM
Brokerages Anticipate Nightstar Therapeutics PLC (NITE) to Announce ($0.19) EPSBrokerages Anticipate Nightstar Therapeutics PLC (NITE) to Announce ($0.19) EPS
www.americanbankingnews.com - January 20 at 9:36 PM
Nightstar Therapeutics PLC (NITE) Forecasted to Post FY2021 Earnings of ($1.18) Per ShareNightstar Therapeutics PLC (NITE) Forecasted to Post FY2021 Earnings of ($1.18) Per Share
www.americanbankingnews.com - January 19 at 11:22 PM
Wedbush Weighs in on Nightstar Therapeutics PLCs FY2022 Earnings (NITE)Wedbush Weighs in on Nightstar Therapeutics PLC's FY2022 Earnings (NITE)
www.americanbankingnews.com - January 18 at 11:32 PM
Nightstar Therapeutics (NITE) Price Target Raised to $31.00 at WedbushNightstar Therapeutics (NITE) Price Target Raised to $31.00 at Wedbush
www.americanbankingnews.com - January 18 at 12:08 AM
Zacks: Brokerages Set $27.80 Target Price for Nightstar Therapeutics PLC (NITE)Zacks: Brokerages Set $27.80 Target Price for Nightstar Therapeutics PLC (NITE)
www.americanbankingnews.com - January 5 at 5:50 PM
Nightstar Therapeutics (NITE) Receives New Coverage from Analysts at Chardan CapitalNightstar Therapeutics (NITE) Receives New Coverage from Analysts at Chardan Capital
www.americanbankingnews.com - January 3 at 6:24 PM
Zacks: Nightstar Therapeutics PLC (NITE) Receives Average Rating of "Strong Buy" from BrokeragesZacks: Nightstar Therapeutics PLC (NITE) Receives Average Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - January 2 at 9:42 PM
Nightstar Therapeutics (NITE) and Its Competitors Financial SurveyNightstar Therapeutics (NITE) and Its Competitors Financial Survey
www.americanbankingnews.com - December 29 at 5:28 AM
 Nightstar Therapeutics PLC Sponsored ADR (NITE) Given Consensus Recommendation of "Strong Buy" by Brokerages Nightstar Therapeutics PLC Sponsored ADR (NITE) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - December 15 at 5:52 AM
Nightstar Therapeutics (NITE) versus The Competition Financial ContrastNightstar Therapeutics (NITE) versus The Competition Financial Contrast
www.americanbankingnews.com - December 12 at 1:40 PM
Nightstar Therapeutics to Participate in BMO Prescriptions for Success Healthcare ConferenceNightstar Therapeutics to Participate in BMO Prescriptions for Success Healthcare Conference
finance.yahoo.com - December 7 at 8:09 AM
 Nightstar Therapeutics PLC Sponsored ADR (NITE) Receives Average Recommendation of "Strong Buy" from Brokerages Nightstar Therapeutics PLC Sponsored ADR (NITE) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - November 28 at 5:44 PM
Zacks: Nightstar Therapeutics PLC Sponsored ADR (NITE) Given Consensus Rating of "Strong Buy" by BrokeragesZacks: Nightstar Therapeutics PLC Sponsored ADR (NITE) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - November 25 at 11:54 AM
Nightstar Announces Pricing of Initial Public OfferingNightstar Announces Pricing of Initial Public Offering
finance.yahoo.com - November 23 at 6:31 PM
Nightstar Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary SharesNightstar Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
finance.yahoo.com - November 23 at 6:31 PM
Nightstar Therapeutics to Participate in Multiple Conferences in NovemberNightstar Therapeutics to Participate in Multiple Conferences in November
finance.yahoo.com - November 23 at 6:31 PM
Nightstar Expands Pipeline with Novel Gene Therapy for the Treatment of Stargardt DiseaseNightstar Expands Pipeline with Novel Gene Therapy for the Treatment of Stargardt Disease
finance.yahoo.com - November 23 at 6:31 PM
 Nightstar Therapeutics PLC Sponsored ADR (NITE) Given Consensus Rating of "Strong Buy" by Analysts Nightstar Therapeutics PLC Sponsored ADR (NITE) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - November 19 at 1:42 PM
Zacks: Nightstar Therapeutics PLC Sponsored ADR (NITE) Given Average Rating of "Strong Buy" by BrokeragesZacks: Nightstar Therapeutics PLC Sponsored ADR (NITE) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - November 3 at 7:50 PM
Nightstar Therapeutics PLC Sponsored ADRs (NITE) Quiet Period Will End  on November 7thNightstar Therapeutics PLC Sponsored ADR's (NITE) Quiet Period Will End on November 7th
www.americanbankingnews.com - November 2 at 1:22 AM
Zacks: Nightstar Therapeutics PLC Sponsored ADR (NITE) Given Consensus Recommendation of "Strong Buy" by AnalystsZacks: Nightstar Therapeutics PLC Sponsored ADR (NITE) Given Consensus Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - October 31 at 5:38 PM
Nightstar Therapeutics PLC Sponsored ADR Expected to Earn Q3 2017 Earnings of ($0.12) Per Share (NITE)Nightstar Therapeutics PLC Sponsored ADR Expected to Earn Q3 2017 Earnings of ($0.12) Per Share (NITE)
www.americanbankingnews.com - October 25 at 7:50 AM
Nightstar Therapeutics PLC Sponsored ADR to Post Q3 2017 Earnings of ($0.19) Per Share, Jefferies Group Forecasts (NITE)Nightstar Therapeutics PLC Sponsored ADR to Post Q3 2017 Earnings of ($0.19) Per Share, Jefferies Group Forecasts (NITE)
www.americanbankingnews.com - October 25 at 7:49 AM
Nightstar Therapeutics PLC Sponsored ADR (NITE) Expected to Earn Q3 2017 Earnings of ($0.14) Per ShareNightstar Therapeutics PLC Sponsored ADR (NITE) Expected to Earn Q3 2017 Earnings of ($0.14) Per Share
www.americanbankingnews.com - October 25 at 7:49 AM
 Nightstar Therapeutics PLC Sponsored ADR (NITE) Receives Consensus Recommendation of "Strong Buy" from Analysts Nightstar Therapeutics PLC Sponsored ADR (NITE) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - October 25 at 12:50 AM
Nightstar Therapeutics Ltd. (NITE) to Raise $76 Million in IPONightstar Therapeutics Ltd. (NITE) to Raise $76 Million in IPO
www.americanbankingnews.com - September 17 at 1:20 AM

SEC Filings

Nightstar Therapeutics (NASDAQ:NITE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Nightstar Therapeutics (NASDAQ:NITE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Nightstar Therapeutics (NASDAQ NITE) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.